VRDN$29.0615.53%3.905
After Hours: 29.72+0.66 +2.29%
Viridian Therapeutics Inc (VRDN)
Date: 2026-11-04 16:00O: 28.27H: 29.74L: 25.07C: 29.06Vol: 11.17M
Viridian Therapeutics Inc stock is traded at $29.06, with a volume of 11,165,399. It is up +15.53% in the last 24 hours and up +49.77% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Previous Close:
$25.15
Open:
$28.27
24h Volume:
11,165,399
Relative Volume:
3.64
Market Cap:
$3.29B
Revenue:
$70.92M
Net Income/Loss:
-$342.21M
P/E Ratio:
-
EPS:
-$3.76
Net Cash Flow:
-$304.30M
1W Performance:
+19.72%
1M Performance:
+49.77%
6M Performance:
+106.65%
1Y Performance:
+28.85%
1-Day Range:
$25.07$29.74
1-Week Range:
$23.97$29.74
52-Week Range:
$13.18$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617.272.4600Address
221 CRESCENT STREET, WALTHAM, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Viridian Therapeutics Inc Stock (VRDN) Insider Trading
- Tousignant JenniferAug 19 '26Chief Legal Officer
- Transaction
- Option Exercise
- Cost
- $14.41
- #Shares
- 10,000
- Value ($)
- 144,100
- #Shares Total
- 10,000
- Tousignant JenniferAug 19 '26Chief Legal Officer
- Transaction
- Sale
- Cost
- $24.50
- #Shares
- 14,212
- Value ($)
- 348,194
- #Shares Total
- 0
- Tousignant JenniferAug 19 '26Officer
- Transaction
- Proposed Sale
- Cost
- $24.50
- #Shares
- 14,212
- Value ($)
- 348,194
- #Shares Total
- 0
- Tripuraneni RadhikaAug 14 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $13.21
- #Shares
- 40,000
- Value ($)
- 528,400
- #Shares Total
- 40,000
- Fairmount Funds Management LLCMay 11 '26Director
- Transaction
- Buy
- Cost
- $17.00
- #Shares
- 1,176,470
- Value ($)
- 19,999,990
- #Shares Total
- 5,090,928
- Beetham Thomas W.Mar 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $30.19
- #Shares
- 3,048
- Value ($)
- 92,004
- #Shares Total
- 0
- Tousignant JenniferMar 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $30.19
- #Shares
- 1,675
- Value ($)
- 50,560
- #Shares Total
- 0
- Harmon SethMar 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $30.19
- #Shares
- 2,031
- Value ($)
- 61,306
- #Shares Total
- 0
- Mahoney Stephen F.Mar 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $30.19
- #Shares
- 7,408
- Value ($)
- 223,610
- #Shares Total
- 0
- Tousignant JenniferDec 31 '25Chief Legal Officer
- Transaction
- Sale
- Cost
- $31.16
- #Shares
- 2,272
- Value ($)
- 70,796
- #Shares Total
- 0
